anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain the titled cosmetic, capable of temporarily smoothing fine wrinkles by coating fine wrinkle parts, e.g. face, neck, etc., and drying the resultant coat and having improved preservation stability, skin safety and practical use characteristics, by blending a montmorillonite group clay mineral with pullulan and water. CONSTITUTION:The titled cosmetic containing 2-8wt% montmorillonite group clay mineral, e.g. montmorillonite, hectorite, bentonite or acid clay, with 5-15wt% pullulan (black yeast) and 75-90wt% water. This cosmetic has action of temporarily smoothing fine wrinkles, e.g. eyelid, corners of the eye, the forehead, mouth, neck, etc., by partially coating the fine wrinkles and drying the resultant coat as well as excellent practical use characteristics, e.g. drying, skin compatibility, wrinkle smoothing effects, persistence of films, etc.
The patients will receive an injection of fluorophore (Anti-GPC3-IRDye800CW) before the surgery. Then intraoperative fluorescence imaging will be performed to guide lesion resection.
Gestational diabetes mellitus is characterised by an insufficient insulin response to hyperglycaemia and the development of insulin resistance. This state has adverse effects on the health outcomes of the mother and child. Existing hyperglycaemia triggers a state of inflammation that involves several tissues, including the placenta. In this study, we analysed the putative pathomechanism of GDM, with special emphasis on the role of chronic, sterile, pro-inflammatory pathways. The expression and regulation of the elements of IL-1β and Toll-like receptor (TLR) pathways in GDM maternal blood plasma, healthy placental explants and a choriocarcinoma cell line (BeWo cell line) stimulated with pro-inflammatory factors was evaluated. Our results indicate elevated expression of the IL-1β and TLR pathways in GDM patients. After stimulation with IL-1β or LPS, the placental explants and BeWo cell line showed increased production of pro-inflammatory IL-6, TNFa and IL-1β together with increased expression of the elements of the signalling pathways. The application of selected inhibitors of NF-ĸB, MAPK and recombinant interleukin 1 receptor antagonist (IL1RA) proved the key involvement of the IL-1β pathway and TLRs in the pathogenesis of GDM. Our results show the possible existence of loops of autocrine stimulation and a possible inflammatory pathomechanism in placentas affected by GDM.
Smart lockers are automated delivery machines. They have been used in dispensing ARVs and Tuberculosis medication to chronically ill patients in South Africa, Kenya, and Eswatini. However, there is no evidence of smart lockers in dispensing chronic disease medication in Nigeria. This study aimed to assess the acceptability of smart lockers in dispensing chronic disease medication and to describe the barriers to accessing care among patients with chronic diseases medication in 5 states in Nigeria. We conducted a cross-sectional study among healthcare workers and patients living with chronic diseases in five Nigerian states of Adamawa, Akwa Ibom, Cross River, Benue, and Niger between November and December 2021. A total of 1,133 participants were recruited (728 patients and 405 healthcare workers). The results revealed that most patients and healthcare workers agreed that using smart lockers for drug dispensing will lead to reduced transportation costs, hospital waiting times, the workload of healthcare workers, and decongestion of health facilities. The majority of the patients living with chronic diseases (43%) and healthcare workers (51%) showed high acceptability for the use of smart lockers. The use of smart lockers in dispensing chronic disease medication in Nigeria is feasible, and patients and healthcare workers are willing to accept the smart lockers, provided that a patient-centred implementation strategy is developed.
Subjects belonging to this group perform a 1-week supervised exercise, following the same training protocol as experimental group (arm 1). This group will not receive cohesive compressive bandage.
This is a study of the safety, tolerability and pharmacokinetics of a Viracept pediatric powder formulation with milk or formula. First a single dose will be administered. After the patient population is divided into 4 groups by age, an optimal dose will be determined for each group. This optimal dose will be given 3 times a day for a 6 week primary observation period, plus an optional 6 month extension.

NOTE: During the single dose portion of this study, patients may be untreated or may continue treatment with their current nucleoside antiretroviral therapy. During multiple dose administration of Viracept, antiretroviral therapy will be intensified by either adding or modifying therapy. Antiretroviral therapies will be limited to those currently licensed including zidovudine, lamivudine, stavudine, didanosine or zalcitabine.
FIELD: medicine, neurology, homeopathy, pharmacology, pharmacy. SUBSTANCE: invention relates to a medicinal agent used for treatment of patients with neurotic and psychotic disturbances with depressive symptomatology that comprises a mixture of two components. One component represents activated form of supersmall doses of monoclonal, polyclonal, immune or natural antibodies raised to brain-specific protein S- 100 and another component represents activated form of supersmall doses of monoclonal, polyclonal, immune or natural antibodies raised to delta sleep-inducing peptide. Activated forms are prepared by multiple successive dilution and external effect being by homeopathic technology mainly. Invention relates also to method for treatment of patients with neurotic and psychotic disturbances with depressive symptomatology that involves administration of a mixture of two components one of that represents activated form of supersmall doses of monoclonal, polyclonal, immune or natural antibodies raised to brain-specific protein S- 100 and another the activated form of supersmall doses of monoclonal, polyclonal, immune or natural antibodies raised to delta sleep-inducing peptide. These activated forms are prepared by multiple successive dilution and external effect being by homeopathic technology mainly. Invention allows preparing a curative agent without expressed adverse effects and can be used for treatment of patients with depressive disturbances. EFFECT: improved preparing method, valuable medicinal properties of agent. 4 cl
Neonates will be placed ventral skin-to-skin position with their mother at least thirty minutes prior the heel lance to give time to calm down following transfer. Skin-to-skin positioning will be taken account comfortable position as possible for mother and the baby, easy to access heel for blood sample and interference minimizing during video recording and continuous NIRS, ECG and oxygen saturation measurement. Skin-to-skin contact will be continued for approximately fifteen minutes after completion of blood sampling. In addition, the neonates will be given a 30% oral glucose solution two minutes prior the heel lance.
Cancer is at least partially attributable to immunological disturbance, and its treatment causes additional inflammatory problems. Chemotherapy-induced peripheral neuropathy (CIPN), especially that induced by oxaliplatin or Taxanes (including paclitaxel and docetaxel) is common among cancer patients during or after the treatment of chemotherapeutic agents, presented as pain and sensory abnormalities for months, and even persists for years in some patients after the cessation of chemotherapy. Even worse is that currently available drugs cannot effectively manage these conditions. Besides, CIPN causes fatigue, anxiety, and depression, which lower patients' quality of life and determination to fight the disease. Interestingly, CIPN is featured by the interference of interleukin (IL) pathways, among which escalation of IL-17 is predominant, suggesting that IL-17 may be manipulated to reduce the inflammation or the immunological disturbance. Cyanidin, a type of glucosides, has been proved to behave like an IL-17 inhibitor and works in an animal model of skin hyperplasia in reducing the IL-17 levels and severity of hyperplasia. We have identified a food material that contains large amounts of glucosides and rutinosides - mulberry juice. Preliminary findings of an ongoing human study of our team have provided statistical evidence that this crude material effectively relieves clinical symptoms of a disorder associated with inflammation features. The current proposal aims to explore the effect of this IL-17 inhibitor-rich material in CIPN and related symptoms. To avoid confounding effects from pain, we plan to divide the potential participants into severe pain and mild pain group to conduct two human studies. A single-blinded randomized controlled design is adopted to compare the effects of this crude material between the experimental group and the control group in (1) pain and CIPN of the severe pain participants and (2) fatigue, anxiety, and depression in the mild pain participants. IL and other immune markers will be tested as evidence of improvement of inflammation status. We expect a decrement in pain, CIPN, fatigue, anxiety, and depression severity with the intake of this IL-17 inhibitor-rich material among cancer patients undergoing chemotherapy.
The investigators will conduct a Stage 1 pilot feasibility study at McLean Hospital to develop and refine a Cognitive Behavioral Therapy (CBT) intervention. Twelve subjects (50% female, ages 18-65) who meet Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) criteria for both marijuana and nicotine dependence and seek treatment to stop using both marijuana and tobacco will receive individual CBT aimed at treating both disorders, as well as Nicotine Replacement Therapy (NRT) in the form of a transdermal nicotine patch. Subjects will start with a 21-mg nicotine patch for 6 weeks, followed by a taper to a 14-mg nicotine patch for 2 weeks and, finally, a 7-mg nicotine patch for 2 weeks. Others will start with a 14-mg patch for 8 weeks followed by a 7-mg patch for 2 weeks. All participants will receive 10 weeks of 1-hour weekly CBT with an experienced clinician. Follow-up visits, scheduled at 4, 6, 8, and 10 weeks, will evaluate of the durability of treatment effects on drug use and psychosocial outcomes.
BACKGROUND: Chronic kidney disease (CKD) is associated with haematological changes, the commonest being anaemia. The number and function of white blood cells (WBC) and platelets are equally affected. Iron deficiency is a common cause of anaemia in the CKD population and anaemia has been associated with reduced cardiac function, increased rates of hospitalization, morbidity and mortality. This study aimed to determine the haematological indices and iron status among pre-dialysis CKD patients.
METHOD: A hospital-based cross-sectional study involving 95 predialysis CKD patients and 95 age- and sex-matched apparently healthy controls. Full blood count, peripheral blood film, serum ferritin, transferrin saturation, C-reactive protein (CRP), electrolytes, urea and creatinine, serum folate and vitamin B12 were done in all study participants. Comparisons were made between results obtained from participants in both groups.
RESULT: The mean ages were 58.1 ± 14.9 years and 58.3 ± 15.0 years in the CKD group and controls, respectively. The male:female ratio was 1:0.9 in both groups. The prevalence of anaemia was 51.6% and 3% in patients with CKD and controls, respectively. There was no significant difference in the total WBC count, neutrophil and lymphocyte differentials, platelet count, serum vitamin B12 and folate in patients with CKD and controls. The prevalence of iron deficiency among patients with CKD was 32.6%, of which 62.5% were absolutely iron-deficient while 37.5% were functionally iron-deficient. The median ferritin and CRP were also higher in CKD. (p =0.001).
CONCLUSION: Anaemia and iron deficiency are common in predialysis CKD patients. Early diagnosis and treatment are important to avoid the problems associated with them.
MOTS-CLÉS: Maladie rénale chronique, Anémie, Carence en fer, Pré-dialyse.
The present invention generally relates to the field of neurological, physiological and psychotic dysfunctions associated with a mental disorder such as schizophrenia, or a predisposition therefor. The invention further relates to genes and proteins, which, when varied in their normal expression, their nucleic acid sequence or in their activity, are associated with the mental disorder. Accordingly, the present invention relates to methods for diagnosis and to methods for prevention and/or treatment of a mental disorder. The present invention additionally relates to compositions for use in diagnosis and to kits for diagnosis of a mental disorder. The invention also relates to the use of a protein or polynucleotide for the manufacture of a medicament for use in the treatment and/or prevention and to a pharmaceutical composition for use in prevention and/or treatment of a mental disorder. Further, the invention relates to methods for screening for a modulator of a mental disorder. More particularly, the present invention relates to methods, compositions and kits, a microarray and reagents for determining the presence of at least one polymorphism and/or at least one combination of polymorphisms of at least one copy of a gene involved in regulating the intracellular glutathione (GSH) level and/or GSH-oxidative stress-related gene expression in a human being. Further, the invention relates to a pharmaceutical composition for use in the treatment and/or prevention of a mental disorder, to the use of an active ingredient such as a protein or polynucleotide for the manufacture of a medicament for use in the treatment and/or prevention of a mental disorder in patients with specific polymorphisms in genes involved in regulating the intracellular GSH level and/or GSH-oxidative stress-related gene expression. The invention also relates to methods of preventing and/or treating a mental disorder comprising administering a medicament to patients having said polymorphisms and to methods of screening for a modulator of a mental disorder.
Limited active drugs are available for the treatment of patients with metastatic colorectal cancer (mCRC) at present and upfront doublet combination of fluoropyrimidines plus either oxaliplatin or irinotecan is regarded as reference strategy for patients appropriate for intensive therapy. Before the era of targeted agents, the treatment strategies in terms of either combination or sequence of cytotoxic agents were rather simple; survival outcomes did not differ according to either the administration sequence of oxaliplatin or irinotecan, or the sequential versus combination chemotherapy in the treatment continuum. However, the treatment strategies have become more complicated in the era of targeted agents.

In case of failure to first-line oxaliplatin plus fluoropyrimidines (FOLFOX or CapeOX) with or without bevacizumab, second-line chemotherapy with FOLFIRI would be administered for treatment continuum, and more various targeted agents can be combined in these setting; bevacizumab beyond progression only in patients who have been treated with first-line bevacizumab plus FOLFOX or CapeOX (TML and BRiTE), cetuximab (only for patients with wild-type KRAS), panitumumab (only for patients with wild-type KRAS), and aflibercept (VELOUR). However, there have been a few valid targeted agents which could be combined in the second line FOLFOX or CapeOX in those progressed after first-line FOLFIRI with or without targeted agents; bevacizumab beyond progression could be a valid treatment strategy only in those received first-line bevacizumab plus FOLFIRI. Higher dose of bevacizumab (10 mg/kg/2-week) could be combined to FOLFOX as second-line chemotherapy; however, it is not recommended at present in terms of cost effectiveness and higher adverse events, and cetuximab plus oxaliplatin-based chemotherapy is neither recommended by current consensus. Thus, there have been unmet needs for the discovery of valid targeted agent combination for the second-line FOLFOX as above reasons.
NEW MATERIAL:A compound expressed by formula I (X is OH group or oxo group bonding to 11 site, 15 site or 16 site of steroid skeleton). EXAMPLE:17alpha-Acetoxy-6-chloro-11beta-hydroxy-2-oxa-4,6-pregnadiene- 3,20-dione. USE:An agent for preventing and treating androgen-dependent disease such as prostatic hyperplasia, prostatic carcinoma, apopecia, etc. and having excellent antiandrogenic hormone activity. PREPARATION:A compound expressed by formula II (-OR1 is bonded to 11 site, 15 site or 16 site of steroid skeleton; R1 is lower alkanoyl) is hydrolyzed by hydrochloric acid, etc., in THF to afford the compound expressed by formula I (X is OH). The resultant compound expressed by formula I is oxidized by further treating the compound, e.g., by Jones reagent consisting of a mixture of chromic acid, sulfuric acid and water to provide the compound expressed by formula I (X is oxo group).
This will have varying settings based on three weight based groups. Small (\<60 kg), medium (60-85 kg), large (\>85 kg). The variables changed are fluoroscopy dose per frame, fluoroscopy frame rate, image acquisition frame rate, thickness of the spectral beam filters, peak tube voltage and peak cathode current. Additional features will also be utilized including live zoom (1.4 factors with 12 inch field of view, FOV), fluoro store and Spot fluoroscopy. Virtual collimation and LIH will be used as needed. This protocol will be applied for 12 weeks.
The present disclosure relates to a system and a method for providing nutritional information using food detection based on image analysis using artificial intelligence. The system comprises: at least one photographing device; a service providing device; and a user terminal. The at least one photographing device obtains at least one image including at least one dish or at least one food contained in the at least one dish. When receiving the at least one image, the service providing device detects at least one object from the at least one image based on a learning model, preprocesses the at least one image from the at least one object is detected, generates a name for each food by recognizing each ingredient from the at least one preprocessed image, maps the each name to the food information included in pre-stored food information based on the name for each generated food, and generates nutritional information by using the mapped food information. When receiving the nutritional information, the user terminal visualizes and displays the nutritional information. A user can conveniently monitor a dietary life in real time.
PURPOSE:A cosmetic capable of beautifying the skin without causing allergy, consisting of an active ingredient obtained by blending ume brandy with eggs under stirring. CONSTITUTION:A cosmetic consisting of an active ingredient obtained by mixing ume brandy with eggs under stirring. The cosmetic is subjected to heat treatment, if necessary. Ume, e.g., an unripe ume, and crystal sugar are immersed in a low- class distilled spirits with high alcoholic content to give ume brandy. Fully frothy eggs are added to the brandy, stirred, and heated optionally to prepare the cosmetic, a yellow transparent liquid material. Though ume brandy has an effect to smooth fine wrinkles, it contain amygdalin harmful to the skin. Eggs prevent the side effects of this injurious material.
Stuttering is a speech disorder in which the flow of speech is disrupted by involuntary repetitions of sounds, syllables, words or phrases, stretched sounds or silent pauses in which the person is unable to produce sounds and sound transitions. Treatment success is the highest if stuttering is treated before the age of 6 years, before it develops into "persistent" stuttering. Stuttering treatment programs that focus directly on the speech of the child, like the Lidcombe Program, have shown to be effective in this age group. Mini-KIDS is also a treatment that focuses directly on the speech of the child. It is possible that capturing the increased brain plasticity at this age in combination with creating optimal conditions for recovery underlie these treatments' success rate. A treatment focusing on the cognitions, emotions and behaviour of the child, the social cognitive behaviour treatment (SCBT), is also frequently delivered in Belgium. In this study we want to compare, and collect data on the effectiveness, of these three treatment programs: Mini-KIDS, SCBT and the Lidcombe Program (protocol registered under number NCT05185726). 249 children will be allocated to one of three treatment groups. Stuttering specialists will treat the child (and guide the parents) with Mini-KIDS, the SCBT or the Lidcombe Program. They will be trained to deliver the programs meticulously. At 18 months after randomisation, the speech fluency of the child and the attitude of the child and parent(s) towards speech will be measured. It is expected that the three programs will achieve the same (near) zero levels of stuttering in nearly all children and a positive attitude towards speech at 18 months after the start of treatment. The amount of treatment hours to reach the (near) zero levels of stuttering will be compared between the different programmes. For families as well as for the health system this could generate important information.
Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light to the tumor on day 2. At least 6 weeks later, patients achieving partial response, no response, or a geographical miss may undergo a second course of treatment.
Subjects will be randomized into three groups (1) standard, weight maintaining diet containing approximately 25-35% protein, 45-55% carbohydrate, 20-30% fat; (2) weight maintaining isocaloric ketogenic diet containing approximately 15-25% protein, 5-10% carbohydrate, 70-80% fat; (3) weight maintaining isocaloric diet containing approximately 15-25% protein, 5-10% carbohydrate, 70-80% fat supplemented with the ketone ester of beta-hydroxy butyrate, 8 grams every 8 hours to further increase the plasma ketone concentration by \~3 mM. Subjects will be further randomized on the basis of:

(i) HbA1c 7.0-8.5% and 8.5-10.5% to ensure similar baseline levels of glucose control and (ii) drug naïve versus drug-treated. At the time of screening, after a 10-12 hour overnight fast, indirect calorimetry will be performed with a ventilated hood system for 60 minutes to measure baseline energy expenditure. An initial weight maintenance energy requirement estimate as 1.5 times resting energy expenditure (obtained by indirect calorimetry) will be started. Diets will consist of a 10-day rotating menu using NutriAdmin for meal planning and Nutrition Maker for analysis of recipes Food will be prepared in the Cafeteria and or the Metabolic Kitchen at the Texas Diabetes Institute and certified by a dietician. Subjects will report to the diet kitchen at 8 AM on Monday through Saturday where they will eat their breakfast and pick up food for their lunch and dinner. On Saturday, participants also will be given food for their Sunday meals. Subjects will maintain a daily dietary log with all food consumed. On each visit subjects will be weighed; dietary log will be reviewed and the caloric content of the diet will be adjusted to maintain the body weight constant. Blood pressure will be measured in the reclining position x 2 separate days. Antidiabetic medications will not be changed during the study unless hypoglycemia (fasting plasma glucose \<70 mg/dl or symptoms) occurs. The study duration will be 10 days which should be sufficient to observe the effect of hyperketonemia on glucose/lipid metabolism and energy expenditure. If participant cannot come on the last days of his/her diet treatment, than we will extend this period up to 13 days and participant will be given diet for additional days till completion of the study visits.